AAAAAA
Results:
1-24
|
Results: 24
Authors:
Andersson, F
Stahl, E
Barnes, PJ
Lofdahl, CG
O'Byrne, PM
Pauwels, RA
Postma, DS
Tattersfield, AE
Ullman, A
Citation: F. Andersson et al., Adding formoterol to budesonide in moderate asthma - health economic results from the FACET study, RESP MED, 95(6), 2001, pp. 505-512
Authors:
Tattersfield, AE
Harrison, TW
Citation: Ae. Tattersfield et Tw. Harrison, Exacerbations of asthma - still room for improvement, LANCET, 358(9282), 2001, pp. 599-601
Authors:
Lofdahl, CG
Potma, DS
Eivindson, A
Schreurs, AJM
Rasidakis, A
Ekstrom, T
Tattersfield, AE
Citation: Cg. Lofdahl et al., On-demand relief treatment for asthma - Reply, LANCET, 357(9271), 2001, pp. 1882-1883
Authors:
Tattersfield, AE
Lofdahl, CG
Postma, DS
Eivindson, A
Schreurs, AGM
Rasidakis, A
Ekstrom, T
Citation: Ae. Tattersfield et al., Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial, LANCET, 357(9252), 2001, pp. 257-261
Authors:
Tattersfield, AE
Town, GI
Johnell, O
Picado, C
Aubier, M
Braillon, P
Karlstrom, R
Citation: Ae. Tattersfield et al., Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years, THORAX, 56(4), 2001, pp. 272-278
Authors:
Walsh, LJ
Wong, CA
Oborne, J
Cooper, S
Lewis, SA
Pringle, M
Hubbard, R
Tattersfield, AE
Citation: Lj. Walsh et al., Adverse effects of oral corticosteroids in relation to dose in patients with lung disease, THORAX, 56(4), 2001, pp. 279-284
Authors:
Harrison, TW
Wisniewski, A
Honour, J
Tattersfield, AE
Citation: Tw. Harrison et al., Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects, THORAX, 56(3), 2001, pp. 186-191
Authors:
Tattersfield, AE
Harrison, TW
Citation: Ae. Tattersfield et Tw. Harrison, Inhaled steroids for COPD?, THORAX, 56, 2001, pp. 2-6
Authors:
Wong, CA
Walsh, LJ
Smith, CJP
Wisniewski, AF
Lewis, SA
Hubbard, R
Cawte, S
Green, DJ
Pringle, M
Tattersfield, AE
Citation: Ca. Wong et al., Inhaled corticosteroid use and bone-mineral density in patients with asthma, LANCET, 355(9213), 2000, pp. 1399-1403
Authors:
Guhan, AR
Cooper, S
Oborne, J
Lewis, S
Bennett, J
Tattersfield, AE
Citation: Ar. Guhan et al., Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects, THORAX, 55(8), 2000, pp. 650-656
Authors:
Tattersfield, AE
Harrison, T
Citation: Ae. Tattersfield et T. Harrison, Asthma guidelines - Reply, THORAX, 55(5), 2000, pp. 441-441
Authors:
Johnson, SR
Tattersfield, AE
Citation: Sr. Johnson et Ae. Tattersfield, Clinical experience of lymphangioleiomyomatosis in the UK, THORAX, 55(12), 2000, pp. 1052-1057
Authors:
Tattersfield, AE
Postma, DS
Barnes, PJ
Svensson, K
Bauer, CA
O'Byrne, PM
Lofdahl, CG
Pauwels, RA
Ullman, A
Citation: Ae. Tattersfield et al., Exacerbations of asthma - A descriptive study of 425 severe exacerbations, AM J R CRIT, 160(2), 1999, pp. 594-599
Authors:
Johnson, SR
Tattersfield, AE
Citation: Sr. Johnson et Ae. Tattersfield, Decline in lung function in lymphangioleiomyomatosis - Relation to menopause and progesterone treatment, AM J R CRIT, 160(2), 1999, pp. 628-633
Authors:
Juniper, EF
Svensson, K
O'Byrne, PM
Barnes, PJ
Bauer, CA
Lofdahl, CGA
Postma, DS
Pauwels, RA
Tattersfield, AE
Ullman, A
Citation: Ef. Juniper et al., Asthma quality of life during 1 year of treatment with budesonide with or without formoterol, EUR RESP J, 14(5), 1999, pp. 1038-1043
Authors:
Bennett, JA
Harrison, TW
Tattersfield, AE
Citation: Ja. Bennett et al., The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects, EUR RESP J, 13(2), 1999, pp. 445-448
Authors:
Edgecombe, J
Wilcock, A
Carr, D
Clarke, D
Corcoran, R
Tattersfield, AE
Citation: J. Edgecombe et al., Dyspnea in the advanced cancer patient, J PAIN SYMP, 18(5), 1999, pp. 313-314
Authors:
Chowdhary, R
Singh, V
Tattersfield, AE
Sharma, SD
Kar, S
Gupta, AB
Citation: R. Chowdhary et al., Relationship of flow and cross-sectional area to frictional stress in airway models of asthma, J ASTHMA, 36(5), 1999, pp. 419-426
Authors:
Tattersfield, AE
Harrison, TW
Citation: Ae. Tattersfield et Tw. Harrison, Step 3 of the asthma guidelines, THORAX, 54(9), 1999, pp. 753-754
Authors:
Walsh, LJ
Wong, CA
Cooper, S
Guhan, AR
Pringle, M
Tattersfield, AE
Citation: Lj. Walsh et al., Morbidity from asthma in relation to regular treatment: a community based study, THORAX, 54(4), 1999, pp. 296-300
Authors:
Tattersfield, AE
du Bois, RM
Citation: Ae. Tattersfield et Rm. Du Bois, Rare diseases - Introduction, THORAX, 54(3), 1999, pp. 253-253
Authors:
Harrison, TW
Oborne, J
Wilding, PJ
Tattersfield, AE
Citation: Tw. Harrison et al., Randomised placebo controlled trial of beta agonist dose reduction in asthma, THORAX, 54(2), 1999, pp. 98-102
Authors:
Tattersfield, AE
Du Bois, RM
Citation: Ae. Tattersfield et Rm. Du Bois, Rare diseases - Authors' reply, THORAX, 54(12), 1999, pp. 1142-1142
Authors:
Harrison, TW
Tattersfield, AE
Citation: Tw. Harrison et Ae. Tattersfield, Effect of single doses of inhaled lignocaine on FEV1 and bronchial reactivity in asthma, RESP MED, 92(12), 1998, pp. 1359-1363
Risultati:
1-24
|